Involvement of the aldo-keto reductase, AKR1B10, in mitomycin-c resistance through reactive oxygen species-dependent mechanisms. 2011

Toshiyuki Matsunaga, and Yumi Yamane, and Keiko Iida, and Satoshi Endo, and Yoshiko Banno, and Ossama El-Kabbani, and Akira Hara
Laboratory of Biochemistry, Gifu Pharmaceutical University, Gifu, Japan. matsunagat@gifu-pu.ac.jp

The human aldo-keto reductase (AKR) 1B10 is suggested as a tumor marker in various solid tumors. Using colon cancer cells, we found that AKR1B10 was induced with acquisition of resistance to the anticancer drug mitomycin-c (MMC). In the resistant cells, treatment with an AKR1B10 inhibitor decreased their MMC tolerance. In the nonresistant cells, overexpression and silencing of AKR1B10 decreased and increased, respectively, susceptibility to cytotoxic effects of MMC and 4-hydroxy-2-nonenal, which was formed as a product of lipid peroxidation by MMC treatment. These results suggest a role of AKR1B10 in the development of MMC resistance, which may be mediated by its ability to detoxify cytotoxic aldehydes including 4-hydroxy-2-nonenal.

UI MeSH Term Description Entries
D003110 Colonic Neoplasms Tumors or cancer of the COLON. Cancer of Colon,Colon Adenocarcinoma,Colon Cancer,Cancer of the Colon,Colon Neoplasms,Colonic Cancer,Neoplasms, Colonic,Adenocarcinoma, Colon,Adenocarcinomas, Colon,Cancer, Colon,Cancer, Colonic,Cancers, Colon,Cancers, Colonic,Colon Adenocarcinomas,Colon Cancers,Colon Neoplasm,Colonic Cancers,Colonic Neoplasm,Neoplasm, Colon,Neoplasm, Colonic,Neoplasms, Colon
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000074408 Aldo-Keto Reductases A family of NADPH-dependent oxidoreductases that reduce carbonyl substrates including sugar-aldehydes, KETOSTEROIDS; keto-prostaglandins, and QUINONES. They are monomers of approximately 37 KDa and are characterized by a parallel beta-8 (BETA SHEET)-alpha 8 (ALPHA HELICES)-barrel structure that contains the NADP binding site. This conformation favors aromatic and apolar substrates. Aldo-Keto Reductase,Aldo-Keto Reductase Family,Aldo-Keto Reductase Superfamily,Aldo Keto Reductase,Aldo Keto Reductase Family,Aldo Keto Reductase Superfamily,Aldo Keto Reductases,Reductase, Aldo-Keto,Reductases, Aldo-Keto
D000447 Aldehydes Organic compounds containing a carbonyl group in the form -CHO. Aldehyde
D000449 Aldehyde Reductase An enzyme that catalyzes reversibly the oxidation of an aldose to an alditol. It possesses broad specificity for many aldoses. EC 1.1.1.21. Aldose Reductase,Aldose Reductase Ia,Aldose Reductase Ib,Erythrose Reductase,Xylose Reductase,Reductase Ia, Aldose,Reductase Ib, Aldose,Reductase, Aldehyde,Reductase, Aldose,Reductase, Erythrose,Reductase, Xylose
D000903 Antibiotics, Antineoplastic Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. Antineoplastic Antibiotics,Cytotoxic Antibiotics,Antibiotics, Cytotoxic
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D015227 Lipid Peroxidation Peroxidase catalyzed oxidation of lipids using hydrogen peroxide as an electron acceptor. Lipid Peroxidations,Peroxidation, Lipid,Peroxidations, Lipid

Related Publications

Toshiyuki Matsunaga, and Yumi Yamane, and Keiko Iida, and Satoshi Endo, and Yoshiko Banno, and Ossama El-Kabbani, and Akira Hara
June 2012, Nihon yakurigaku zasshi. Folia pharmacologica Japonica,
Toshiyuki Matsunaga, and Yumi Yamane, and Keiko Iida, and Satoshi Endo, and Yoshiko Banno, and Ossama El-Kabbani, and Akira Hara
May 2011, Chemico-biological interactions,
Toshiyuki Matsunaga, and Yumi Yamane, and Keiko Iida, and Satoshi Endo, and Yoshiko Banno, and Ossama El-Kabbani, and Akira Hara
November 2008, Chemical research in toxicology,
Toshiyuki Matsunaga, and Yumi Yamane, and Keiko Iida, and Satoshi Endo, and Yoshiko Banno, and Ossama El-Kabbani, and Akira Hara
March 2009, Chemico-biological interactions,
Toshiyuki Matsunaga, and Yumi Yamane, and Keiko Iida, and Satoshi Endo, and Yoshiko Banno, and Ossama El-Kabbani, and Akira Hara
December 2013, The Journal of biological chemistry,
Toshiyuki Matsunaga, and Yumi Yamane, and Keiko Iida, and Satoshi Endo, and Yoshiko Banno, and Ossama El-Kabbani, and Akira Hara
May 2012, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc,
Toshiyuki Matsunaga, and Yumi Yamane, and Keiko Iida, and Satoshi Endo, and Yoshiko Banno, and Ossama El-Kabbani, and Akira Hara
January 2021, Advances in experimental medicine and biology,
Toshiyuki Matsunaga, and Yumi Yamane, and Keiko Iida, and Satoshi Endo, and Yoshiko Banno, and Ossama El-Kabbani, and Akira Hara
November 2013, FEBS letters,
Toshiyuki Matsunaga, and Yumi Yamane, and Keiko Iida, and Satoshi Endo, and Yoshiko Banno, and Ossama El-Kabbani, and Akira Hara
June 2015, Chemico-biological interactions,
Toshiyuki Matsunaga, and Yumi Yamane, and Keiko Iida, and Satoshi Endo, and Yoshiko Banno, and Ossama El-Kabbani, and Akira Hara
November 2010, Archives of biochemistry and biophysics,
Copied contents to your clipboard!